Searchable abstracts of presentations at key conferences in endocrinology

ea0037gp.03.02 | Adrenal (2) | ECE2015

Androgens and erythropoiesis in females: an insight from patients with congenital adrenal hyperplasia

Karunasena Nayananjani , Ross Richard J , Daniel Eleni

Background: Androgens promote erythropoiesis and have been used for the treatment of anaemia. Furthermore, polycythemia is a known side effect of androgen therapy. In congenital adrenal hyperplasia (CAH), elevated adrenal androgens cause virilisation of female patients. Glucocorticoid treatment reduces androgen levels but there is a difficult balance between excess androgens and suppressed androgens due to excess glucocorticoid treatment.Aim of study: To...

ea0065oc3.3 | Bone and Calcium | SFEBES2019

Generation of a long acting parathyroid hormone hybrid analogue through fusion to a binding protein

Sorour Lina , Ross Richard J , Wilkinson Ian R

Hypoparathyroidism causes severe hypocalcaemia and defective skeletal metabolism. Treatment with calcium and vitamin D supplementation can cause kidney failure whilst native parathyroid hormone (PTH) requires repeated injections and causes renal impairment paralleling high peak and low trough PTH levels. A long-acting PTH, providing constant physiological levels, is needed. LA-PTH, a hybrid of PTH and PTH related peptide, prolongs cAMP responses via altered receptor mechanisms...

ea0049gp61 | Cardiovascular & Lipid Endocrinology | ECE2017

Constructing a long-acting leptin analogue

Sendur Suleyman Nahit , Wilkinson Ian R , Ross Richard J

Introduction: Leptin is a 16-kDa peptide hormone secreted by adipose tissue and acts as a sensor for energy stores. It feedsback at the hypothalamic arcuate nucleus to suppress appetite. Leptin treatment has been highly effective in suppressing appetite in the rare cases of leptin-deficient obesity and improving the metabolic profile in congenital generalised lipodystrophy. These patients require 2.5–10 mg once daily recombinant leptin treatment. We hypothesised that prol...

ea0035oc5.2 | Adrenal & Thyroid | ECE2014

Relationship between final height and cardiometabolic risk and quality of life in adults with congenital adrenal hyperplasia: United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE)

Han Thang S , Conway Gerard S , Krone Nils , Aled Rees D , Stimson Roland H , Arlt Wiebke , Walker Brian R , Ross Richard J

Background: Treatment of CAH in childhood focuses on growth and development; however the impact of final height (FH) on adult health is not known. We examined the relationship between FH, adiposity, cardiometabolic risk and quality of life (QoL) in a cohort of adult patients.Methods: Cross-sectional analysis of 199 adults with CAH. FH, waist circumference (WC) and QoL were expressed as z-scores adjusted for mid-parental target height (FHTH<...

ea0031p331 | Steroids | SFEBES2013

Quality of life relates to glucocorticoid treatment regimen, adiposity and insulin resistance in adults with congenital adrenal hyperplasia: UK Congenital adrenal Hyperplasia Adult Study Executive (CaHASE)

Han Thang S , Krone Nils , Willis Debbie S , Conway Gerard S , Aled Rees D , Stimson Roland H , Walker Brian R , Arlt Wiebke , Ross Richard J

Background: Quality of life (QoL) has been variously reported as normal or impaired in congenital adrenal hyperplasia (CAH) adults. We found impaired QoL in UK CAH adults and now report the relationship between QoL, glucocorticoid treatment and health outcomes in these patients.Methods: Cross-sectional analysis of 151 CAH adults with 21-hydroxylase deficiency aged 18–69 years in whom QoL (SF-36), glucocorticoid regimen, anthropometric, and metabolic...

ea0073pep1.5 | Presented ePosters 1: Adrenal and Cardiovascular Endocrinology | ECE2021

Modified-release hydrocortisone improves androgen excess and facilitates glucocorticoid dose reduction in patients with classic congenital adrenal hyperplasia: non-invasive monitoring in saliva and urine

Prete Alessandro , Baranowski Elizabeth S. , Lina Schiffer , Adaway Joanne E. , Hawley James M. , Keevil Brian G. , Porter John , Ross Richard J. , Arlt Wiebke

BackgroundStandard glucocorticoid (GC) therapy in classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OHD-CAH) is often inadequate in controlling adrenal androgen excess, leading to GC over-exposure and poor health outcomes. A novel modified-release formulation of hydrocortisone (MR-HC, Chronocort® Diurnal Ltd. UK) has been shown to improve circulating adrenal androgen excess in 21-OHD-CAH. We investigated whether saliva and ...